INTRODUCTION
The objective of this study was to evaluate the accuracy of using intravesical prostatic protrusion (IPP) as a parameter for the diagnosis of prostate adenoma (PA), as well as to determine the relationship between the site of PA and bladder outlet obstruction. IPP was determined with the use of transabdominal ultrasonography (TAUS).
MeThODs A total of 77 consecutive adult men aged 30-85 years with haematuria or undergoing checkup for bladder tumour were enrolled. International Prostate Symptom Score (IPSS), and the results of uroflowmetry, TAUS and cystourethroscopy were assessed. All cases of IPP were classified into grades 0 (no IPP), 1 (1-5 mm), 2 (6-10 mm) or 3 (> 10 mm). PA diagnosis was confirmed using flexible cystourethroscopy. The sites of PA were classified as U0 (no adenoma), U1 (lateral lobes), U2 (middle lobe) or U3 (lateral and middle lobes). confirmed on cystourethroscopy. When the tip of the flexible scope is placed at the verumontanum of patients without PA blocking the prostatic urethra, the bladder cavity can be seen in the distance. However, in patients with PA blocking the prostatic urethra, the view would be distorted. Although it is accepted that bladder outlet obstruction (BOO) can only be diagnosed or confirmed on pressure flow study, flexible cystourethroscopy would be able to assess the presence or absence of PA, which could be causing varying degrees of obstruction.
LUTS is a common clinical problem in ageing males.
However, not all patients with LUTS have PA. (4) Therefore, it is important to first determine whether a patient with LUTS has PA. However, diagnosing PA can be challenging, not only because LUTS is found in conditions other than PA, but also because prostate volume correlates poorly with obstruction and the symptoms of PA. (5) (6) (7) PAs that cause marked obstruction may also be seen in patients with a small prostate. Furthermore, a small group of patients with PA may develop chronic retention associated with renal impairment because they have no symptoms. (8) Although PA is routinely diagnosed by pathologists, it is important that a clinical diagnosis of PA be made possible, and that the diagnosis can be made in a simple and noninvasive manner.
The use of transabdominal ultrasonography (TAUS) to measure prostate size and intravesical protrusion of the prostate (IPP) has been shown to be useful for the assessment of patients with LUTS suggestive of BPH. (9, 10) IPP occurs as the PA enlarges into the bladder, along the plane of least resistance.
The enlargement of either the middle or lateral lobes or even both lobes may cause IPP. This can be seen and easily measured and classified on TAUS. Previous studies on IPP have focused on its ability to predict the obstruction or progression of clinical BPH (i.e. PA). (11) (12) (13) (14) The primary objective of the present study was to and a complete physical examination that included digital rectal examination (DRE). The bladder and prostate were then assessed by TAUS (Aloka SSD-1700; Hitachi Aloka, Tokyo, Japan) with a comfortably full bladder (capacity 150-250 mL).
Prostate volume was determined using the prolate ellipsoid formula in the transverse plane. IPP was measured from the tip of the protruding prostate to the base of the prostate at the circumference of the bladder in the sagittal plane. (13) IPP was classified according to the various degrees: grade 0 (no IPP), grade 1 (1-5 mm), grade 2 (6-10 mm) or grade 3
(> 10 mm) (Fig. 3 ). After TAUS assessment, peak urinary flow 3c 3d rate (Qmax) was determined using a uroflowmeter (Urodyn 1000 Medtronic; Medtronic, Skovlunde, Denmark). Post-void residual urine volume (PVR) was also measured using TAUS.
Patients then underwent cystourethroscopy to confirm whether the prostate was normal or had PA. Bladder findings were noted using standard charts for PA configurations. 
ResUlTs
The mean age, IPSS score, QOL score, prostate volume and In previous studies, we demonstrated the correlation of IPP with BOO using pressure flow study, as well as the use of IPP in predicting the progression of benign prostatic obstruction. (11, 12) These findings have been validated by studies from other centres. (14, 16) In the present study, all patients with IPP were confirmed to have PA on flexible cystourethroscopy.
In general, clinical BPH has been defined as a prostate volume of > 20 g. However, we found that 29 of the 37 (78.4%) patients in our study group with a prostate volume of < 20 g still had IPP, and all patients with IPP in our study were diagnosed with PA. This finding provides further evidence that small prostates may contain PA and may even cause marked BOO. (1, 2) Compared to prostate volume, IPP is better able to predict BOO. (17) IPP is a simple parameter to use in diagnosing PA that causes various degrees of obstruction.
The use of IPP in the diagnosis of PA is advantageous as it is easily measured at the bedside with ultrasonography and is noninvasive, unlike transrectal ultrasonography and flexible cystourethroscopy.
In our study, we found that IPP had the highest specificity Indeed, in a previous study conducted by our group, 59% of the 408 enrolled patients with LUTS suggestive of PA could be watched, only 9% required surgical treatment and 32%
were on pharmacotherapy. (22) In the present study, we found that patients with IPP had PA, and propose the combination of IPP evaluation and The present study was not without limitations. First, observations made on flexible cystourethroscopy were subjective. However, although experience is needed to assess whether the PA is causing significant obstruction, it is relatively easy to determine the presence or absence of an adenoma.
Also, as a measure to ensure uniformity and reduce biasness while these assessments were performed, charts displaying the various configurations of PA were used. Second, the present study had a relatively small sample size. Since all of the enrolled patients either had haematuria or were undergoing checkup for bladder tumour, only four patients were found to have a normal prostate in the our study group. If we had recruited a higher number of healthy adult men, the proportion of individuals with normal prostate might have been higher.
More extensive studies that include a larger number of patients are needed to confirm our findings.
PA was confirmed in all patients with IPP on flexible cystourethroscopy. PAs located in the middle of the prostatic urethra (middle lobe) were found to be more obstructive than those located in the lateral position (lateral lobes). We propose IPP as a novel parameter for the diagnosis of PA. As PA can also be present in patients without IPP, patients who have poor urinary flow rate in the absence of IPP may need to undergo UDS or flexible cystourethroscopy to determine the cause of poor uroflow.
